To ensure that every Roche product is both effective and safe, we have designed processes to optimise patient safety throughout the lifecycle of a medicine, from the clinical trials to post-launch.
Roche has an established Pharmacovigilance (PV) system to monitor for suspected side effects of medicines and medical devices, during clinical trials and after they are available for use in the wider population. Whenever new safety information is identified, we evaluate all available safety data to update the product safety profile (e.g. update product label) as appropriate. Monitoring the safe use of medicines and medical devices, gives us a better understanding of the risk-benefit profile and can help both patients and healthcare professionals make informed decisions about treatments.
Pharmacovigilance is a key contributor to the Healthcare System as it allows for better understanding of side effects and patient risk factors. Evidence-based use of medicines ensures that each patient can receive optimum treatment based on their individual circumstances such as existing/prior medical history and medications. An informed patient can better cope with his or her condition and therapies, increasing the adherence to treatment, and finally, the success rate of treatment.
Our aim is to work collaboratively with all stakeholders including patients, families, policy makers, health care leaders, health workers and patient organisations towards co-designing safety interventions that reflect the needs and preferences of patients, ultimately enhancing healthcare safety globally.
Patients, carers, and health care professionals are encouraged to report all side effects to